Analyst firms · Oppenheimer · PODD

Oppenheimer PODD price target and rating history

Insulet Corporation (PODD) · Health Care

Oppenheimer rates Insulet Corporation (PODD) Perform with a $365 price target, as of its latest action on Aug 5, 2026. It has published 3 rating actions on PODD since January 2022, including 1 upgrade and 1 downgrade. Across 10 firms with a PODD price target in the last 12 months, the median target is $182.

Current rating

Perform

Price target

$365

Median target, all firms

$182

Actions on PODD

3

Oppenheimer price target on PODD

Every Oppenheimer rating on PODD

• Aug 5, 2026
  DowngradeOppenheimer downgrades to Perform from Outperform
• Sep 8, 2025
  ResumeOppenheimer resumes coverage at Outperform, price target $365
• Jan 31, 2022
  UpgradeOppenheimer upgrades to Outperform from Perform, price target $300 to $275

How other firms rate PODD

Each firm's latest rating and stated target in the last 12 months.

Questions about Oppenheimer and PODD

What is Oppenheimer's price target for PODD?

Oppenheimer's latest stated price target for Insulet Corporation (PODD) is $365, from its action on Sep 8, 2025.

What is Oppenheimer's rating on PODD?

Oppenheimer rates PODD Perform, a neutral rating, as of Aug 5, 2026.

When did Oppenheimer last change its view on PODD?

On Aug 5, 2026, Oppenheimer downgrades to Perform from Outperform.

How does Oppenheimer's PODD target compare with other analysts?

Across 10 firms with a PODD price target in the last 12 months, the median target is $182.

More PODD rating histories

• Barclays3
• Leerink Partners4
• UBS3
• Citigroup3
• Wolfe Research4
• Morgan Stanley5

All Oppenheimer ratingsPODD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.